Business Context and Reporting Period
This Form 8-K is filed by BioSig Technologies, Inc. (not Streamex Corp.) on October 11, 2017. The company is an emerging growth company incorporated in Delaware. The report details the consummation of the ninth closing under a Unit Purchase Agreement dated April 6, 2017.
Key Financial Metrics
The filing reports a specific capital raise event rather than periodic financial performance metrics.
- Capital Raised (Current Event): $580,000 aggregate consideration.
- Securities Issued: 386,667 Units.
- Unit Composition: One share of Common Stock and one warrant to purchase 0.5 shares of Common Stock.
- Price per Unit: $1.50.
- Warrant Exercise Price: $1.50 per share.
- Revenue, Profit, Cash Flow, Debt, and Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes and Historical Context
This transaction represents the ninth closing under the Purchase Agreement. The filing provides a summary of previous closings under the same agreement:
- First Closing (April 6, 2017): 426,667 Units for $640,000.
- Second through Fifth Closings (April–June 2017): 399,933 Units for $599,898.
- Sixth Closing (July 13, 2017): 267,002 Units for $400,500.
- Seventh Closing (August 18, 2017): Units issued; specific count and consideration not detailed in this text.
- Eighth Closing (September 20, 2017): 103,334 Units for $155,000.
Guidance, Risks, and Unusual Items
Unregistered Sales: The securities were sold in reliance on the exemption from registration under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933. All investors represented they were accredited investors.
Registration Rights: In connection with this closing, investors became parties to a Registration Rights Agreement dated April 6, 2017.
Outlook and Guidance: The filing text does not provide a clear value for future guidance or management commentary on operational outlook.
Investor Verification Checklist
- Verify the total aggregate capital raised across all nine closings under the April 6, 2017 Purchase Agreement.
- Confirm the specific number of units and consideration for the seventh closing (August 18, 2017), which is not explicitly quantified in this text.
- Review the Registration Rights Agreement to understand future liquidity options for these investors.
- Check subsequent filings for the impact of this equity issuance on the company's capitalization table and potential dilution.